Cargando…

Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial

BACKGROUND: Intrauterine adhesions (IUA) are the most common cause of uterine infertility and are caused by endometrium fibrotic regeneration following severe damage to the endometrium. Although current stem cell treatment options using different types of autologous stem cells have exhibited some be...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yun, Sun, Haixiang, Zhu, Hui, Zhu, Xianghong, Tang, Xiaoqiu, Yan, Guijun, Wang, Jingmei, Bai, Donghui, Wang, Juan, Wang, Liu, Zhou, Qi, Wang, Huiyan, Dai, Chengyan, Ding, Lijun, Xu, Biyun, Zhou, Yan, Hao, Jie, Dai, Jianwu, Hu, Yali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042450/
https://www.ncbi.nlm.nih.gov/pubmed/29996892
http://dx.doi.org/10.1186/s13287-018-0904-3
_version_ 1783339156831731712
author Cao, Yun
Sun, Haixiang
Zhu, Hui
Zhu, Xianghong
Tang, Xiaoqiu
Yan, Guijun
Wang, Jingmei
Bai, Donghui
Wang, Juan
Wang, Liu
Zhou, Qi
Wang, Huiyan
Dai, Chengyan
Ding, Lijun
Xu, Biyun
Zhou, Yan
Hao, Jie
Dai, Jianwu
Hu, Yali
author_facet Cao, Yun
Sun, Haixiang
Zhu, Hui
Zhu, Xianghong
Tang, Xiaoqiu
Yan, Guijun
Wang, Jingmei
Bai, Donghui
Wang, Juan
Wang, Liu
Zhou, Qi
Wang, Huiyan
Dai, Chengyan
Ding, Lijun
Xu, Biyun
Zhou, Yan
Hao, Jie
Dai, Jianwu
Hu, Yali
author_sort Cao, Yun
collection PubMed
description BACKGROUND: Intrauterine adhesions (IUA) are the most common cause of uterine infertility and are caused by endometrium fibrotic regeneration following severe damage to the endometrium. Although current stem cell treatment options using different types of autologous stem cells have exhibited some beneficial outcomes in IUA patients, the reported drawbacks include variable therapeutic efficacies, invasiveness and treatment unavailability. Therefore, the development of new therapeutic stem cell treatments is critical to improving clinical outcomes. METHODS: Twenty-six patients who suffered from infertility caused by recurrent IUA were enrolled in this prospective, non-controlled, phase I clinical trial with a 30-month follow-up. During the procedure, 1 × 10(7) umbilical cord-derived mesenchymal stromal cells (UC-MSCs), loaded onto a collagen scaffold, were transplanted into the uterine cavity following an adhesion separation procedure. Medical history, physical examination, endometrial thickness, intrauterine adhesion score and the biological molecules related to endometrial proliferation and differentiation were assessed both before and 3 months after cell therapy. RESULTS: No treatment-related serious adverse events were found. Three months after the operation, the average maximum endometrial thickness in patients increased, and the intrauterine adhesion score decreased compared to those before the treatment. A histological study showed the upregulation of ERα (estrogen receptor α), vimentin, Ki67 and vWF (von Willebrand factor) expression levels and the downregulation of ΔNP63 expression level, which indicates an improvement in endometrial proliferation, differentiation and neovascularization following treatment. DNA short tandem repeat (STR) analysis showed that the regenerated endometrium contained patient DNA only. By the end of the 30-month follow-up period, ten of the 26 patients had become pregnant, and eight of them had delivered live babies with no obvious birth defects and without placental complications, one patient in the third trimester of pregnancy, and one had a spontaneous abortion at 7 weeks. CONCLUSIONS: Transplanting clinical-grade UC-MSCs loaded onto a degradable collagen scaffold into the uterine cavity of patients with recurrent IUA following adhesiolysis surgery is a safety and effective therapeutic method. TRIAL REGISTRATION: Clinicaltrials.gov. NCT02313415, Registered December 6, 2014. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13287-018-0904-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6042450
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60424502018-07-13 Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial Cao, Yun Sun, Haixiang Zhu, Hui Zhu, Xianghong Tang, Xiaoqiu Yan, Guijun Wang, Jingmei Bai, Donghui Wang, Juan Wang, Liu Zhou, Qi Wang, Huiyan Dai, Chengyan Ding, Lijun Xu, Biyun Zhou, Yan Hao, Jie Dai, Jianwu Hu, Yali Stem Cell Res Ther Research BACKGROUND: Intrauterine adhesions (IUA) are the most common cause of uterine infertility and are caused by endometrium fibrotic regeneration following severe damage to the endometrium. Although current stem cell treatment options using different types of autologous stem cells have exhibited some beneficial outcomes in IUA patients, the reported drawbacks include variable therapeutic efficacies, invasiveness and treatment unavailability. Therefore, the development of new therapeutic stem cell treatments is critical to improving clinical outcomes. METHODS: Twenty-six patients who suffered from infertility caused by recurrent IUA were enrolled in this prospective, non-controlled, phase I clinical trial with a 30-month follow-up. During the procedure, 1 × 10(7) umbilical cord-derived mesenchymal stromal cells (UC-MSCs), loaded onto a collagen scaffold, were transplanted into the uterine cavity following an adhesion separation procedure. Medical history, physical examination, endometrial thickness, intrauterine adhesion score and the biological molecules related to endometrial proliferation and differentiation were assessed both before and 3 months after cell therapy. RESULTS: No treatment-related serious adverse events were found. Three months after the operation, the average maximum endometrial thickness in patients increased, and the intrauterine adhesion score decreased compared to those before the treatment. A histological study showed the upregulation of ERα (estrogen receptor α), vimentin, Ki67 and vWF (von Willebrand factor) expression levels and the downregulation of ΔNP63 expression level, which indicates an improvement in endometrial proliferation, differentiation and neovascularization following treatment. DNA short tandem repeat (STR) analysis showed that the regenerated endometrium contained patient DNA only. By the end of the 30-month follow-up period, ten of the 26 patients had become pregnant, and eight of them had delivered live babies with no obvious birth defects and without placental complications, one patient in the third trimester of pregnancy, and one had a spontaneous abortion at 7 weeks. CONCLUSIONS: Transplanting clinical-grade UC-MSCs loaded onto a degradable collagen scaffold into the uterine cavity of patients with recurrent IUA following adhesiolysis surgery is a safety and effective therapeutic method. TRIAL REGISTRATION: Clinicaltrials.gov. NCT02313415, Registered December 6, 2014. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13287-018-0904-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-07-11 /pmc/articles/PMC6042450/ /pubmed/29996892 http://dx.doi.org/10.1186/s13287-018-0904-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Cao, Yun
Sun, Haixiang
Zhu, Hui
Zhu, Xianghong
Tang, Xiaoqiu
Yan, Guijun
Wang, Jingmei
Bai, Donghui
Wang, Juan
Wang, Liu
Zhou, Qi
Wang, Huiyan
Dai, Chengyan
Ding, Lijun
Xu, Biyun
Zhou, Yan
Hao, Jie
Dai, Jianwu
Hu, Yali
Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial
title Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial
title_full Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial
title_fullStr Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial
title_full_unstemmed Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial
title_short Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial
title_sort allogeneic cell therapy using umbilical cord mscs on collagen scaffolds for patients with recurrent uterine adhesion: a phase i clinical trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042450/
https://www.ncbi.nlm.nih.gov/pubmed/29996892
http://dx.doi.org/10.1186/s13287-018-0904-3
work_keys_str_mv AT caoyun allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT sunhaixiang allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT zhuhui allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT zhuxianghong allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT tangxiaoqiu allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT yanguijun allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT wangjingmei allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT baidonghui allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT wangjuan allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT wangliu allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT zhouqi allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT wanghuiyan allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT daichengyan allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT dinglijun allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT xubiyun allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT zhouyan allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT haojie allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT daijianwu allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial
AT huyali allogeneiccelltherapyusingumbilicalcordmscsoncollagenscaffoldsforpatientswithrecurrentuterineadhesionaphaseiclinicaltrial